Results 181 to 190 of about 74,897 (307)

Shared Lineage, Distinct Outcomes: Yap and Taz Loss Differentially Impact Schwann and Olfactory Ensheathing Cell Development Without Disrupting GnRH‐1 Migration

Glia, Volume 73, Issue 10, Page 2077-2097, October 2025.
Main Points OECs, SCs, and Mel derive from SCPs. Sox10Cre;YapHet;TazKO mice show impaired SC maturation, reduced Mel formation, fewer SCPs, OECs, and olfactory neurons, but normal GnRH‐1 neuron migration. ABSTRACT Olfactory Ensheathing Cells (OECs) are glial cells originating from the neural crest and are critical for bundling olfactory axons to the ...
Ed Zandro M. Taroc, Enrico Amato Jr., Alexis M. Semon, Nikki Dolphin, Briane Beck, Sophie Belin, Yannick Poitelon, Paolo E. Forni   +7 more
wiley   +1 more source

Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study. [PDF]

PLoS One
Chen Y, Lu W, Liao R, Zhang X, Chen W, Wang J, Feng H.   +6 more
europepmc   +1 more source

Dependence of secretory responses to gonadotropin-releasing hormone on diacylglycerol metabolism. Studies with a diacylglycerol lipase inhibitor, RHC 80267.

, 1988
J.P. Chang, Reginald O. Morgan, Kevin Catt   +2 more
openalex   +1 more source

Cancer and fertility management: FIGO best practice advice

International Journal of Gynecology &Obstetrics, Volume 171, Issue 1, Page 32-44, October 2025.
Abstract Cancer diagnoses in patients of reproductive age require balancing urgent oncological treatment with the need to preserve fertility. This FIGO Best Practice Advice outlines key considerations for fertility management in this population given the rising cancer incidence among young women and the reproductive risks posed by cancer treatments ...
Nikhil Purandare, Francisco Ruiloba, Long Nguyen‐Hoang, Sarikapan Wilailak, Nozomu Yanaihara, Jacqueline P. W. Chung, Jaideep Malhotra, Edgar Mocanu, Frédéric Amant, Orla McNally, Inge Peters, Katie Flynn, Aya El Helali, Cynthia Maxwell, Sumaiya Adam, Lina Bergman, Surabhi Nanda, Valerie Tiempo Guinto, Fionnuala M. McAuliffe, Catherine Nelson‐Piercy, Melanie Nana, Graeme Smith, Jonathan Berek, Sharleen O'Reilly, Pat O'Brien, Bo Jacobsson, Liona C. Poon, on behalf of the FIGO Committee on the Impact of Pregnancy on Long‐term Health and the FIGO Division of Maternal and Newborn Health and in collaboration with the FIGO Committee on Women's Cancer and the FIGO Committee on Reproductive Medicine, Endocrinology and Infertility   +28 more
wiley   +1 more source

Effects of Different Gonadotropin-Releasing Hormone Agonists on IVF/ICSI-ET Outcomes in Long Protocol: A Retrospective Study. [PDF]

Int J Womens Health
Xu M, Li H, Zhao Y, Li H, Zhao C, Zhang X, Ni R, Liang J, Xu J.   +8 more
europepmc   +1 more source

Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

MedComm, Volume 6, Issue 10, October 2025.
In TME, undetectable DCCs (panel A) join with a low tumor burden along with low immune suppression, that favor successful immune manipulation through immune suppression inhibiting immune‐therapy. This moves the immune balance toward the immune response and likely makes more stable the dormant state of DCCs in the unstable metastatic niche and/or allows
Andrea Nicolini, Paola Ferrari, Roberto Silvestri, Dario A. Bini   +3 more
wiley   +1 more source

Decreased Circulating Gonadotropin-Releasing Hormone Associated with Keratoconus. [PDF]

Cells
Escandon P, Choi AJ, Mabry S, Nicholas SE, Cunningham RL, Redden L, Murphy DA, Riaz KM, McKay TB, Karamichos D.   +9 more
europepmc   +1 more source

Gonadotropin-releasing hormone action upon luteinizing hormone bioactivity in pituitary gland: role of sulfation.

, 1987
Maria L. Sardañons, Ángela R. Solano, Ernesto J. Podestá   +2 more
openalex   +1 more source

G Protein‐Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers

MedComm, Volume 6, Issue 10, October 2025.
G protein‐coupled receptors (GPCRs) are the dynamic protein family in the human genome. GPCR dysregulation aids in the advancement of cancer through increased migration, survival, and proliferation. Novel treatments that target GPCR signaling include orthosteric ligands, biased receptor mutants, PROTACs, and antibody–drug conjugates.
Inamu Rashid Khan, Sana Khurshid, Saud Almawash, Rakesh Kumar, Ammira S. Al‐Shabeeb Akil, Ajaz A. Bhat, Muzafar A. Macha   +6 more
wiley   +1 more source

The Double-Edged Nature of the Gonadotropin-Releasing Hormone Agonist (GnRHa) Long Protocol: A Case of Paradoxical Ovarian Hyperstimulation During the Expected Downregulation Phase. [PDF]

J Clin Med
Nádasdi B, Kovács P, Csajbók ÉA, Wellinger K, Vágvölgyi A, Zádori J.   +5 more
europepmc   +1 more source